What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?

British Journal of Ophthalmology

Volumn 98, Issue SUPPL. 1, 2014, Pages

  Avery, Robert L ^a  

^a California Retina Consultants   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; FC RECEPTOR; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANTIGEN BINDING; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CEREBROVASCULAR ACCIDENT; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; IC 50; NONHUMAN; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; RETROLENTAL FIBROPLASIA; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION;

ANGIOGENESIS; DRUGS; MACULA; PHARMACOLOGY; RETINA;

ANGIOGENESIS INHIBITORS; HUMANS; INTRAVITREAL INJECTIONS; RETINAL DISEASES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84901195961     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-303844     Document Type: Article

References (45)

1. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695-705.
2. Acharya NR, Sittivarakul W, Qian Y, et al. Bilateral effect of unilateral ranibizumab in patients with uveitis-related macular edema. Retina 2011;31:1871-6.
3. Bakbak B, Ozturk BT, Gonul S, et al. Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye. J Ocul Pharmacol Ther 2013;29:728-32.
4. Matsuyama K, Ogata N, Matsuoka M, et al. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010;94:1215- 18.
5. Carneiro AM, Costa R, Falcão MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 2012;90:e25-30.
6. Zehetner C, Kirchmair R, Huber S. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 2013;97:454-9.
7. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411.
8. Harding SP. IVAN Outcomes [abstract]. Invest Ophthalmol Vis Sci 2013;54. ARVO E-Abstract.
9. Avery RL, Castellarin A, Steinle N, et al. Comparison of Systemic Pharmacokinetics Post Anti-VEGF Intravitreal Injections of Ranibizumab, Bevacizumab and Aflibercept (abstract). Presented at the 2013 Annual Meeting of the American Society of Retina Specialists (ASRS); Toronto, 25 August 2013.
10. Zimmermann R, Koenig J, Zingsem J, et al. Effect of specimen anticoagulation on the measurement of circulating platelet-derived growth factors. Clin Chem 2005;51:2365-8. (Pubitemid 41692585)
11. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011;56:95-113.
12. Miki K, Miki A, Matsuoka M, et al. Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. Ophthalmology 2009;116:1748-54.
13. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-82. (Pubitemid 350181137)
14. Avery RL, Le K, Lu T, et al. Visual Acuity Response as a Function of the Affinity and Vitreous Half-Life of Intravitreally-Administered Anti-VEGF Agents (abstract). Presented at the ASRS; Las Vegas, 28 August 2012.
15. Maguire MG, Daniel E, Shah AR, et al. Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2013;120:2035-41.
16. Lucentis US Prescribing Information 2013, page 10. http://www.accessdata. fda.gov/drugsatfda-docs/label/2013/125156s081lbl.pdf (accessed 9/10/2013).
17. Yu L, Liang XH, Ferrara N. Comparing protein VEGF inhibitors: In vitro biological studies. Biochem Biophys Res Commun 2011;408:276-81.
18. Tuomi L, Zhang Y, Visich J. Pharmacokinetics of intravitreal ranibizumab in patients with neovascular age-related macular degeneration, retinal vein occlusion, and diabetic macular edema [abstract]. Invest Ophthalmol Vis Sci 2012;53 ARVO E-Abstract 4178.
19. Avery RL. Anti-Therapeutic Antibody Analyses of Ranibizumab 0.5 mg or 2.0 mg in Patients With Wet Age-related Macular Degeneration. Presented at Angiogenesis, Exudation, and Degeneration 2013, Miami Fla, 9 Feb 2013.
20. Eylea US Prescribing Information 2013, page 15. http://www.accessdata. fda.gov/drugsatfda-docs/label/2013/125387s015s020lbl.pdf (accessed 9/10/2013).
21. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171-85.
22. Thai H-T, Veyrat-Follet C, Vivier N, et al. A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects. Br J Clin Pharmacol 2011;72:402-14.
23. Avastin US Prescribing Information 2013, page 3. http://www.accessdata. fda.gov/drugsatfda-docs/label/2013/125085s267lbl.pdf (accessed 9/10/2013).
24. Zaltrap US Prescribing Information 2013, page 1. http://www.accessdata. fda.gov/drugsatfda-docs/label/2012/125418s000lbl.pdf (accessed 9/10/2013).
25. Schmucker C, Ehlken C, Agostini HT, et al. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS ONE 2012;7:e42701.
26. Kodijian L. GEFAL Outcomes. IOVS 2013;54. ARVO E-Abstract.
27. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
28. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
29. http://cteu.bris.ac.uk/trials/ivan/PIGPSafetyLetter.pdf (accessed 9/10/2013).
30. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258-67.
31. Avery RL. Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: promise and concern. J AAPOS 2009;13:329-31.
32. Mintz-Hittner HA, Kennedy KA, Chuang AZ, et al. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603-15.
33. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin®). Retina 2006;26:262-9. (Pubitemid 44318177)
34. Kim H, Robinson SB, Csaky KG. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 2009;15:2803-12.
35. Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012;153:327-33.
36. Karaca C, Oner AO, Mirza E, et al. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity. JAMA Ophthalmol 2013;131:1099-101.
37. Lutty GA, McLeod DS, Bhutto I, et al. Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog. Invest Ophthalmol Vis Sci 2011;52:4039-47.
38. Avery RL. Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both? J AAPOS 2012;16:2-4.
39. Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116:1731-9.
40. Bressler NM, Boyer DS, Williams DF, et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina 2012;32:1821-8.
41. Alexander SL, Linde-Zwirble WT, Werther W, et al. Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology 2007;114:2174-8. (Pubitemid 350181138)
42. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Public- assessment-report/human/002392/WC500135744.pdf (accessed 9/10/2013).
43. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-22.
44. Avery R, Francom S, Tuomi L, et al. Meta-analysis examining the systemic safety profile of intravitreal ranibizumab injections in AMD, RVO, and DME [abstract]. IOVS 2013;54:ARVO E-Abstract 1535.
45. Curtis LH, Hammill BG, Schulman KA, et al. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128:1273-9.